Date
Category Sartorius Stedim Biotech S.A. Press Release

Sartorius Stedim Biotech and Novasep to develop novel systems for membrane chromatography

Göttingen, March 05, 2019

Sartorius Stedim Biotech (SSB), a leading supplier for the biopharmaceutical industry, and Novasep based in Pompey, France, have entered into a collaboration agreement in the area of chromatography and single-use bioprocessing. Novasep provides various products and services to the life science industry, based on specialized technologies. In particular, this company is a recognized system provider with substantial expertise in the design, manufacture and control of resin-based batch and continuous chromatography systems.


Novasep’s established BioSC® platform and SSB’s single use technology will form the basis for the development of innovative chromatography systems. Systems currently on the market are designed for resins, but do not take full advantage of membrane chromatography capabilities. Optimally run membrane chromatography processes will provide the most attractive alternative to batch and continuous resin-based chromatography - namely higher productivity, smaller scale operations and increased robustness.


Systems designed for membrane chromatography applications are a part of SSB’s global product strategy to supply complete solutions for upstream and downstream processing in life sciences. “Membranes are the embodiment of process intensification. As the market leader in membrane chromatography, Sartorius Stedim Biotech aims to realize this potential and offer customers the full benefits of our Sartobind portfolio,” explained Dr. Fritjof Linz, Head of Separation at Sartorius Stedim Biotech. “We are happy to work with a highly competent partner like Novasep to introduce new membrane chromatography technology for flow through and capture applications,” the Sartorius manager added.


Nadège Laborde, President Process Solutions at Novasep, commented: “This collaboration is a wonderful opportunity for Novasep and Sartorius Stedim Biotech, as it leverages the core capabilities of the two companies. The result of this venture will satisfy the latest market demands for continuous processing, process intensification, performance, and ease of use.”


This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.